Viral infection of central nervous system
MONDO:0024318Also known as: viral infection of central nervous system, central nervous system viral infection, viral disease of central nervous system
61 clinical trials for this condition and its sub-types, 3 tagged with Viral infection of central nervous system itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Viral infection of central nervous system
-
Poliomyelitis 28 trials · 39 incl. sub-types
3 sub-types
- Postpoliomyelitis syndrome 11 trials
- Acute nonparalytic poliomyelitis 0 trials
- Paralytic poliomyelitis 0 trials Sub-types →
-
Viral encephalitis 3 trials · 17 incl. sub-types
12 sub-types
- Tick-borne encephalitis 6 trials
- Mosquito-borne viral encephalitis 0 trials · 5 incl. sub-types Sub-types →
- Herpes simplex encephalitis 2 trials
- Acute hemorrhagic encephalitis 0 trials · 1 incl. sub-types Sub-types →
- Acute necrotizing encephalitis 1 trial
- Eastern equine encephalitis 1 trial
- Colorado tick fever 0 trials
- HHV-6 encephalitis 0 trials
- Powassan encephalitis 0 trials
- Borna virus encephalitis 0 trials
- Encephalitis lethargica 0 trials
- Subacute sclerosing panencephalitis 0 trials
-
Venezuelan equine encephalitis 1 trial
-
Lymphocytic choriomeningitis 1 trial
-
Geniculate herpes zoster 0 trials
-
Meningitis caused by poliovirus 0 trials
Most studied deeper sub-types
-
New west nile vaccine enters first human tests
Vaccine OngoingThis early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will comp…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
One shot, six protections: could a single vaccine replace multiple infant shots?
Vaccine OngoingThis trial tests a new vaccine called LBVD, which combines protection against six diseases: diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib. The study enrolls healthy infants around 6 to 8 weeks old who receive three doses at 6, 10, and 14 weeks of age. Researche…
Phase 2/3 • Sponsor: LG Chem • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis trial is testing an experimental vaccine made from virus-like particles (VLPs) that mimic polio viruses without causing disease. It aims to see if this vaccine is safe and triggers a strong immune response in healthy infants starting at 6 weeks old and toddlers aged 12-18 mo…
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
-
New vaccine aims to stop rare but deadly brain infections from mosquitoes
Vaccine OngoingThis Phase 2 trial tests a new vaccine called MVA-BN-WEV to prevent two types of equine encephalitis (Eastern and Venezuelan), which are rare but serious brain infections spread by mosquitoes. The study involves 411 healthy adults aged 18-50 and aims to find the best dose and dos…
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 07:52 UTC
-
Which vaccine schedule keeps children protected longest?
Prevention OngoingThis trial tests different vaccination schedules for Japanese encephalitis in healthy children starting at 8 months old. Researchers compare how well each schedule triggers and maintains protective antibodies through age 6, including the effect of booster doses. The study also mo…
Phase 4 • Sponsor: Liaoning Chengda Biotechnology CO., LTD • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can virtual walking trick the brain into easing chronic pain?
Symptom relief OngoingResearchers are testing whether a virtual walking program can reduce chronic pain and psychological distress in people with severe mobility impairment, mostly from spinal cord injuries or polio. Participants wear a head-mounted display and use a controller to guide an avatar thro…
Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New clinic aims to break the cycle of useless tests for fatigue sufferers
Symptom relief OngoingThis study tests a new, team-based rehabilitation program for 125 working-age adults with persistent physical symptoms and chronic fatigue. The program includes doctors, therapists, and counselors who work together to help patients manage their symptoms and improve daily function…
Sponsor: Turku University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Scientists compare immune responses to viral and bacterial infections in ICU patients
Knowledge-focused OngoingThis study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive review of viral meningitis cases aims to sharpen diagnosis
Knowledge-focused OngoingThis study looks back at 4000 patients who had a suspected viral infection of the brain or spinal cord. Researchers will analyze which viruses were found and how the illness progressed in different groups, including children, adults, and people with weakened immune systems. The g…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Simple test may uncover hidden tick-borne brain infections
Knowledge-focused By invitation onlyThis study reviews medical records of 200 people hospitalized with unexplained meningitis or meningoencephalitis. Researchers want to see if adding a test for tick-borne encephalitis (TBE) helps find more cases. No new drug or treatment is being tested—only the impact of a change…
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC